Vikasolum

General characteristics. Structure:

Active ingredient: sodium Menadionum bisulphite – 10 ml.

Excipients - sodium disulphite, Acidum hydrochloricum solution, water for injections.

Pharmacological properties:

Pharmacodynamics. The water-soluble analog of vitamin K (K3 vitamin), is a coenzyme K-epoksidreduktazy vitamin which participates in synthesis of blood-coagulation factors ІІ, VII, IX and X, and proteins of C and S. Has indirect haemo static effect due to synthesis of de novo of the corresponding blood-coagulation factors. The beginning of effect after intramuscular introduction - in 8-24 h.

Pharmacokinetics. After intramuscular introduction it is easily and quickly distributed. In insignificant quantities collects in fabrics. Having quickly passed a cycle of metabolic activation, in a liver is oxidized to a thiol form. It is removed by kidneys and with bile it is almost exclusive in the form of metabolites. High concentration of vitamin K in Calais are caused by its synthesis by intestinal microflora.

Indications to use:

Prothrombinopenia (prevention and treatment) caused by deficit of vitamin K:

- disturbance of a blood coagulation owing to decrease in maintenance of factors of II, VII, IX, X, against the background of reception of some medicines (indirect anticoagulants - derivative coumarin and an indandion, salicylates, some antibiotics) $

- disturbance of absorption of vitamin K in intestines (especially at obturatsionny jaundice), abetalipoproteinemiya, parenteral food.

Preventively at surgical interventions with possible severe parenchymatous bleeding.

Route of administration and doses:

Intramusculary.

Prothrombinopenia (prevention and treatment) caused by deficit of vitamin K. The single dose for children is more senior than 14 years and adult - 10-15 mg, daily - 30 mg. To children: 1-2 years - 6 mg/days, 3-4 years - 8 mg/days, 5-9 years - 10 mg/days, 10-14 years - 15 mg/days.

Treatment duration - 3-4 days, after a 4-day break repeat a course.

At surgical interventions with possible severe parenchymatous bleeding appoint within 2-3 days before operation.

Features of use:

Purpose of drug is shown only in case vitamin K reception inside is impossible. In a type of the postponed approach of haemo static effect drug is not used for a stop of bleedings. At hemophilia and Verlgof's disease drug is inefficient.

Side effects:

Allergic reactions: hyperemia of the person, skin rash (including erythematic, small tortoiseshell), skin itch, bronchospasm.

From system of blood: hemolitic anemia, hemolysis at newborn children with inborn deficit glyukozo-6-fosfatdegidrogenazy.

Local reactions: pain and hypostasis in an injection site, damage of skin in the form of spots at repeated injections to the same place.

Others: a hyperbilirubinemia, jaundice (including a kernicterus at babies); seldom - dizziness, tranzitorny decrease in the ABP, "profuse" sweat, tachycardia, "weak" filling of pulse, change of flavoring feelings.

Interaction with other medicines:

Weakens effect of indirect anticoagulants - derivative coumarin and an indandion.

Does not influence anticoagulating activity of heparin.

Simultaneous use with antibiotics of a broad spectrum of activity, quinidine, quinine, salicylates in high doses, antibacterial sulfonamides demands increase in a dose of vitamin K (owing to disturbance of its synthesis by intestinal microflora).

Co-administration with hemolitic medicines increase risk of hemolitic anemia.

Contraindications:

Hypersensitivity to drug components, hypercoagulation, a thrombembolia, hemolitic anemia, the neonatality period, pregnancy, the period of childbirth, children's age till 1 year.

With care: liver failure, pregnancy.

Overdose:

Symptoms: the vitamin K hypervitaminosis which is shown giperprotrombinemiy, hemolitic anemia, a hyperbilirubinemia. In isolated cases, especially at children, spasms develop.

Treatment: drug withdrawal. Under control of indicators of coagulant system of blood appoint anticoagulants.

Storage conditions:

To store in the dry place protected from light at a temperature not above 25 °C. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Solution for intramuscular introduction of 10 mg/ml on 1 ml or 2 ml in ampoules.

5 ampoules in a blister strip packaging from a film polyvinyl chloride.

1 or 2 blister strip packagings together with the application instruction, a knife ampoule or the scarificator ampoule in a pack from a cardboard.

5 or 10 ampoules together with the application instruction, a knife ampoule or the scarificator ampoule in a pack from a cardboard with a corrugated insert.

When using ampoules with a point or a ring of a break the knife ampoule or the scarificator ampoule is not put.